RxDoctor Payments Data

Kellie Harkness, APRN

Family · Olympia, WANPI 1720541683

Payments from drug & device makers

$1,283in general payments, 2019–2025

Across 73 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$347
  • AstraZeneca$228
  • Otsuka America Pharmaceutical, Inc.$118
  • Lilly USA, LLC$116
  • Boehringer Ingelheim$109
  • Novo Nordisk$86
  • plus $280 from 8 others

What the payments were for

  • Food & beverage$1,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,283 in reported general payments places this provider in the 80th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$29,609
Medicare patients
148
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$57,708
OzempicSemaglutide38$47,948
EliquisApixaban33$44,133
XareltoRivaroxaban18$21,592
FarxigaDapagliflozin Propanediol11$16,765
Serevent DiskusSalmeterol Xinafoate12$7,935
EntrestoSacubitril/Valsartan11$7,443
Breo ElliptaFluticasone/Vilanterol15$7,412
InvokanaCanagliflozin12$6,725
MyrbetriqMirabegron12$5,418
Albuterol Sulfate HfaAlbuterol Sulfate124$3,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$3,432
Levothyroxine Sodium323$2,682
Atorvastatin Calcium262$2,590
Losartan Potassium179$1,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$109$57,70838 claims
Novo NordiskOzempic$86$47,94838 claims
PfizerEliquis$67$44,13333 claims
AstraZenecaFarxiga$228$16,76511 claims
AbbVieSynthroid$347$63222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,706 family providers in Washington.

Other family in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →